On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Initiates Collaborative Research Program with Viatar for Early Pancreatic Cancer Detection

Company: Interpace Diagnostics Group, Inc. (IDXG)
Category: Stock Spotlights

Interpace Diagnostics (NASDAQ: IDXG) is trading higher on news of its collaborative research program with Viatar CTC Solutions Inc. The partnership will combine Viatar’s circulating tumor cell collection technology with Interpace’s commercialized PancraGEN™ assay used to help assess unknown pancreatic cancer biopsies in patients with pancreatic cysts. Studies are being designed to identify patients most likely to develop pancreatic cancer in the near future as well as to detect pancreatic cancer at its earliest stage of development. These studies may lead to the enactment of early diagnostic testing and assessment for patients with pancreatic diseases, as well as for those predisposed to the development of this form of cancer in need of early and accurate detection. The pre-clinical studies are anticipated to happen over the next six months. “We are pleased to partner with Viatar, a company dedicated to CTC’s and in combination with our PancraGEN assay we are hopeful of providing early detection, prognosis and disease monitoring by way of liquid biopsies for pancreatic cancer at its earliest stage of detection, ” Interpace Diagnostics president and CEO Jack E. Stover stated in the news release.

To view the full press release, visit: http://nnw.fm/cQ0Sq

About Interpace Diagnostics Group

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace’s mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics’ website at www.interpacediagnostics.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Contact us: 212.418.1217